NBE-Therapeutics’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

NBE Therapeutics is a biotechnology company that develops and commercializes antibody-drug conjugates for the treatment of cancer. Read more

Bertrand Damour's photo - CEO of NBE-Therapeutics

CEO

Bertrand Damour

CEO Approval Rating

90/100

Founded:

2012

Status:

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Calypso is NBE-Therapeutics's top competitor. Calypso was founded in 2013 in Plan-les-Ouates, Geneva. Calypso competes in the Biotechnology field. Calypso generates $21.4M more revenue than NBE-Therapeutics.

Vir is perceived as one of NBE-Therapeutics's biggest rivals. Vir's headquarters is in San Francisco, California, and was founded in 2016. Vir is in the Biotechnology industry. Vir generates 415% of NBE-Therapeutics's revenue.

ADC Therapeutics is one of NBE-Therapeutics's top competitors. ADC Therapeutics is a Public company that was founded in Epalinges, Vaud in 2011. ADC Therapeutics operates in the Biotechnology industry. ADC Therapeutics has 111 more employees vs. NBE-Therapeutics.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is 27 a good estimate for NBE-Therapeutics's Employee count?

Acquisitions

No recent acquisitions found related to NBE-Therapeutics

NBE-Therapeutics Funding History

$2.4M$5.4M$26M$46.1M$68.1M

Since NBE-Therapeutics was founded in 2012, it has participated in 5 rounds of funding. In total NBE-Therapeutics has raised $68.1M. NBE-Therapeutics' last funding round was on Jan 2020 for a total of $22.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series C
Jan 2020
$22M

Boehringer Ingelheim Venture Fund

Series B
Jun 2018
$20.1M

PPF Group

Series B
Nov 2016
$20.6M

PPF Group

Series A
Mar 2015
$3.1M
Seed
Dec 2013
$2.4M
-

Total Funding: $68.1M

Since NBE-Therapeutics was founded in 2012, it has participated in 5 rounds of funding. In total NBE-Therapeutics has raised $68.1M. NBE-Therapeutics' last funding round was on Jan 2020 for a total of $22.0M

Investments

No recent investments found related to NBE-Therapeutics

NBE-Therapeutics News

November 7, 2019startupticker

SOTIO expands collaboration with NBE Therapeutics

In 2016 SOTIO and NBE Therapeutics have entered into a partnership. The two companies will now develo... See more »
October 29, 2019startupticker

Biotech startups strengthen their teams

Cutiss, NBE Therapeutics and Stalicla have grown their teams. As per October, the newly appointed mem... See more »
April 15, 2019Manufacturing Chemist

Swiss NBE-Therapeutics chooses WuXi Biologics as manufacturing partner

Chinese-Swiss partnership will focus on developing and manufacturing anti-ROR1 ADC products for clini... See more »
March 13, 2019BioPortfolio

NBE to Present LateBreaking Abstract on Lead ADC Program NBE002 ROR1 at the AACR Annual Meeting

BASEL Switzerland March 13 2019 B3C newswire NBETherapeutics AG a biopharmaceutical company developin... See more »
November 15, 2018BioPortfolio

Dr. Anthony Tolcher Joins the Scientific Advisory Board of NBETherapeutics

Basel Switzerland November 15 2018 B3C newswire NBE Therapeutics AG a biopharmaceutical company devel... See more »
October 1, 2018BioPortfolio

NBETherapeutics AG Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13082018 Prices from USD $250

SummaryNBETherapeutics AG NBETherapeutics is a biotechnology company that focuses on the development ... See more »
July 28, 2018BioPortfolio

NBETherapeutics AG Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 23042018 Prices from USD $250

SummaryNBETherapeutics AG NBETherapeutics is a biotechnology company that focuses on the development ... See more »

Headquarters

Hochbergerstrasse 60C Technology Park Basel

Basel, Basel-Country4057

41-61-633-2230

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

NBE Therapeutics is a biotechnology company that develops and commercializes antibody-drug conjugates for the treatment of cancer. NBE-Therapeutics was founded in 2012. NBE-Therapeutics' headquarters is located in Basel, Basel-Country, CH 4057. It has...

CEO

NBE-Therapeutics's CEO, Bertrand Damour, currently has an approval rating of 90%. NBE-Therapeutics's primary competitors are Calypso, Vir & ADC Therapeutics.

Website

nbe-therapeutics.com

Frequently Asked Questions about NBE-Therapeutics

  1. When was NBE-Therapeutics founded?

    NBE-Therapeutics was founded in 2012
  2. Who is NBE-Therapeutics's CEO?

    NBE-Therapeutics's CEO is Bertrand Damour
  3. How much revenue does NBE-Therapeutics generate?

    NBE-Therapeutics generates $5M in revenue
  4. How much funding does NBE-Therapeutics have?

    NBE-Therapeutics has historically raised $68.1M in funding
  1. Where is NBE-Therapeutics's headquarters?

    NBE-Therapeutics's headquarters is in Basel Basel-Country, CH
  2. How many employees does NBE-Therapeutics have?

    NBE-Therapeutics has 27 employees
  3. What sector does NBE-Therapeutics operate in?

    NBE-Therapeutics is in Health Care Services
  4. Who are NBE-Therapeutics's competitors?

    NBE-Therapeutics's top competitors are Calypso, Vir, ADC Therapeutics